In 2014, a new molecule, LCZ696, was presented in the global PARADIGM-HF randomized trial, which is a combination of the neprilysin inhibitor (sacubitril) with the angiotensin II receptor blocker (ARB) (valsartan) [1,2]. This evidence concerns the gene MME and hydrops fetalis.